Skip to search formSkip to main contentSkip to account menu

LY 518674

Known as: LY-518674, LY518674 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PropionatesTriazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.
AIMS Fibrate medications weakly stimulate the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and are… 
Highly Cited
2009
Highly Cited
2009
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
2009
2009
Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome
Objective—The study of PPAR-α activation on apoA-I production in humans has been limited to fibrates, relatively weak PPAR… 
Highly Cited
2008
Highly Cited
2008
Effects of Fibrate Drugs on Expression of ABCA1 and HDL Biogenesis in Hepatocytes
Fibric acid-shaped drugs raise high-density lipoprotein (HDL) cholesterol by upregulating the HDL-related genes through… 
2008
2008
Potent and Selective PPAR-Agonist LY 518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome
Objective—The study of PPARactivation on apoA-I production in humans has been limited to fibrates, relatively weak PPARagonists… 
2007
2007
Abstract 681: Treatment With A Potent & Selective PPAR-{alpha} Agonist LY518674 Significantly Increases ApoA-I and ApoA-II Production Rates In Patients With Metabolic Syndrome Despite No Change In…
2007
2007
Use of CXCL10 levels to predict thyroid autoimmunity following IFN-α therapy
  • Nature Clinical Practice Endocrinology…
  • 2007
  • Corpus ID: 33280623
Fibrates are widely prescribed agonists of transcription factor peroxisome proliferatoractivated receptor (PPAR)-α, and are used… 
2005
2005
propyl } phenoxy ) propanoic Acid ( LY 518674 ) , That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression
Low high-density lipoprotein-cholesterol (HDL-c) is an important risk factor of coronary artery disease (CAD). Optimum therapy… 
2004
2004
1116-31 Induction of marked changes in serum lipids and apolipoprotein A-1 expression in human Apo A-1 transgenic mice by a novel peroxisome proliferator-activated receptor alpha agonist LY518674
2003
2003
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
A new series of hPPARalpha agonists containing a 2,4-dihydro-3H-1,2,4-triazol-3-one (triazolone) core is described leading to the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)